Agoracom: Small Cap Investment - Valeo Pharma Inc. - AGORACOM Small Cap 60: What Gives Valeo Pharma The Competitive Advantage on its Asthma Drugs

A revenue-generating, small-cap Canadian pharmaceutical company

Revenue Projected at $150,000,000 by 2025

Reply New Message

Back To Forum List View

agoracom administrator

Rank: Administrator [?]

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

AGORACOM Small Cap 60: What Gives Valeo Pharma The Competitive Advantage on its Asthma Drugs

posted on Nov 17, 2021 11:28AM

Reply New Message

Back To Forum List View

Please to post a reply